Aquestive Therapeutics Released Topline Pharmacokinetic Data From Its Crossover Study AQ109103 For Anaphylm (Epinephrine) Sublingual Film; Plans To Submit Pivotal PK Study Protocol To The FDA In Early August, And Expects To Commence Pivotal PK Trial In Q4
Portfolio Pulse from Benzinga Newsdesk
Aquestive Therapeutics has released topline pharmacokinetic data from its crossover study AQ109103 for Anaphylm (Epinephrine) Sublingual Film. The company plans to submit a pivotal PK study protocol to the FDA in early August and expects to commence a pivotal PK trial in Q4.
July 27, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aquestive Therapeutics' release of positive topline data for its Anaphylm study and plans for further FDA submissions and trials could potentially boost investor confidence and the company's stock price.
The release of positive topline data indicates progress in Aquestive Therapeutics' product development, which could attract investor interest. The company's plans to submit a pivotal PK study protocol to the FDA and commence a trial in Q4 further demonstrate its commitment to advancing its product pipeline, which could positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100